CD38-targeted Bispecific ADC

The CD38 ADC (antibody-drug conjugate) has emerged as a promising therapeutic approach in the treatment of multiple myeloma and other CD38-expressing malignancies. By leveraging the specificity of monoclonal antibodies targeting CD38, this ADC delivers a highly potent cytotoxic agent directly to cancer cells, thus minimizing off-target effects and enhancing antitumor activity. The CD38 ADC exploits the overexpression of the CD38 antigen on the surface of malignant cells to ensure selective cytotoxicity, reducing damage to normal tissues. As research progresses, the CD38 ADC is continually optimized to improve its therapeutic index, offering new hope for patients suffering from hematologic cancers and potentially expanding its use into solid tumors and other conditions characterized by CD38 expression.